Fortress Biotech

Fortress Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fortress Biotech (FBIO) as of Oct 19, 2026 is -70.22 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -106.27 M USD — a change of -33.93% (higher).

EBITDA

-70.22 MUSD

YoY

-33.93%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fortress Biotech is 2025 -70.22 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fortress Biotech was 2024 -106.27 M USD. It decreases by -33.93% higher compared to the previous year.

The Fortress Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-121.56 M USD
Jan 1, 2019
-110.82 M USD
Jan 1, 2020
-94.27 M USD
Jan 1, 2021
-188.54 M USD
Jan 1, 2022
-203.05 M USD
Jan 1, 2023
-141.72 M USD
Jan 1, 2024
-106.27 M USD
Jan 1, 2025
-70.22 M USD
The Fortress Biotech EBITDA history
YEAREBITDAYoY
-70.22 MUSD-33.93%
-106.27 MUSD-25.01%
-141.72 MUSD-30.20%
-203.05 MUSD+7.69%
-188.54 MUSD+100.00%
-94.27 MUSD-14.93%
-110.82 MUSD-8.84%
-121.56 MUSD+30.32%
-93.28 MUSD+37.99%
-67.60 MUSD+33.78%
-50.53 MUSD+144.68%
-20.65 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Fortress Biotech Stock analysis

What does Fortress Biotech do? Fortress Biotech Inc. is a biopharmaceutical company based in New York City, operating in the Health Care sector with a focus on biotechnology. The company develops and commercializes novel pharmaceutical and biotechnology products through its 11 operating subsidiaries, which include 4 commercial-stage programs and 25 development-stage programs targeting therapeutic areas such as Immuno-oncology, Hematology, Gene Therapy, and Rare Diseases. Fortress employs 78 full-time staff and was listed on the stock market on 17 November 2011. Fortress Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fortress Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fortress Biotech is -70.22 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Fortress Biotech changed from -106.27 M USD to -70.22 M USD, representing a -33.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Fortress Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Fortress Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Fortress Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Fortress Biotech